ReviewCytokine & growth factor reviews2021
Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors.
Review in Cytokine & growth factor reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- IFIT3: a crucial mediator in innate immunity and tumor progression with therapeutic implications.Frontiers in immunology · 2025Review
- IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes.International journal of molecular sciences · 2024Article
- The interplay of aging, adipose tissue, and COVID-19: a potent alliance with implications for health.GeroScience · 2024Review
- Aging mitochondria in the context of SARS-CoV-2: exploring interactions and implications.Frontiers in aging · 2024Review
- Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.Signal transduction and targeted therapy · 2023Review
- SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?International journal of molecular sciences · 2023Review
- Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV.Vaccines · 2023Article
- The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2.Pathogens (Basel, Switzerland) · 2022Review
- The Coronavirus pandemic - 2022: Viruses, variants & vaccines.Cytokine & growth factor reviews · 2022Article
- Review
- Type I Interferons in COVID-19 Pathogenesis.Biology · 2021Review
- Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 is a recently identified coronavirus accountable for the current pandemic disease known as COVID-19. Different patterns of disease progression infer a diverse host immune response, with interferon (IFN) being pivotal. IFN-I and III are produced and released by virus-infected cells during the interplay with SARS-CoV-2, thus establishing an antiviral state in target cells. However, the efficacy of IFN and its role in the possible outcomes of the disease are not yet defined, as it is influenced both by factors inherent to the virus and to the host. The virus exhibits multiple strategies to counteract the innate immune response, including those shared by SARS-CoV and MERS-CoV and other novel ones. Inborn errors in the host may affect IFN-related effector proteins or decrease its levels in plasma upon neutralization by preexistent autoantibodies. This battle between the IFN response triggered upon SARS-CoV-2 infection, its magnitude and timing, and the efficacy of its antiviral tools in dispute against the viral evasion strategies together with the genetic factors of the host, generate a scenario whose fate contributes to defining the severity of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.